Full Text of PDF (315k)
Article in Japanese
Abstract
Case Report
A case of lung cancer with exacerbated Mycobacterium avium lung disease under pembrolizumab treatment
Taro Hirabayashi Kei Sonehara Shuhei Nozawa Yuichi Ikuyama Masamichi Komatsu Masayuki Hanaoka
First Department of Internal Medicine, Shinshu University School of Medicine
ABSTRACT
A 74-year-old man with stage IVB lung adenocarcinoma received combination therapy of cytotoxic anti-cancer agents and pembrolizumab as first-line treatment. Mycobacterium avium had been identified in tracheal secretions acid-fast bacillus culture at the time of the lung cancer diagnosis. After two cycles of combination therapy and 14 cycles of pembrolizumab, infiltration shadows in the lung showed disease exacerbation. The patient discontinued pembrolizumab and multiple antibiotic treatment for M. avium lung disease was administered. After 5 months, the infiltration shadows improved, and the sputum acid-fast bacillus culture became negative. We report the case because the association between immunotherapy and pulmonary nontuberculous mycobacteriosis remains unclear.
KEYWORDS
Lung cancer Immunotherapy Pembrolizumab Pulmonary nontuberculous mycobacteriosis Mycobacterium avium
Received 24 Mar 2022 ／ Accepted 25 May 2022
AJRS, 11(5): 301-304, 2022
Copyright © The Japanese Respiratory Society All Rights Reserved.